Deborah Mariottini

I'll research this attorney before drafting.

Let me verify PTAB/IPR involvement and additional case details.

Deborah J. Mariottini — patent litigation practice summary

Focus areas. Mariottini is an associate in Desmarais LLP's New York office whose practice centers on complex technology disputes — patent litigation, PTAB proceedings, licensing disputes, and international arbitration. Her stated technical experience runs to biotechnology, medical devices, and computer networking, rather than Wi-Fi/standards-essential or mechanical work. The case list tracks no technology field, but the public record shows her on life-sciences and diagnostic patents (non-invasive prenatal testing, patent licensing/arbitration for a biotech company and a research laboratory), robotic surgical devices, and networking patent defense.

Side preference. The structured data records two appearances, both defense-side, both at Desmarais (one as counsel, one as lead counsel), with no plaintiff-side appearances. That count should be read with caution: the tracked entries are untitled and the public record shows substantial plaintiff-side work — Desmarais's own site and W.D. Tex./D. Del. dockets list Mariottini as counsel (and, in Ravgen v. Natera, as a pro hac vice lead attorney) for patent owner Ravgen, Inc. Her docketed defense work includes Auris Health, Cisco, and IBM. On the available evidence she works both sides, predominantly for patent owners in the Ravgen campaign and for operating companies in defense; the "0 plaintiff / 2 defendant" split in the supplied data appears incomplete rather than indicative of a defense-only practice.

Firm context and notable matters. She has been at Desmarais LLP since 2019 (summer associate 2017, 2018), apart from a 2018 summer associate stint at Paul, Weiss; no other firm practice is sourced. Her most prominent work is the Ravgen non-invasive prenatal testing campaign: she conducted the direct examinations of Ravgen's clinical expert and the source-code technical expert in the $272.5M LabCorp jury verdict (W.D. Tex., Sept. 2022), later enhanced by $100M for willfulness (total $372.5M; post-trial challenges rejected Feb. 2025), and in the $57M Natera verdict (Jan. 2024). Desmarais reports Federal Circuit affirmances in January 2025 preserving $429.5M, plus settlements with Illumina, PerkinElmer, and Quest. On defense she is named in Intuitive Surgical v. Auris Health (D. Del., robotic surgery) and in the Orckit v. Cisco and DigitalDoors v. IBM (E.D. Tex.) defense teams.

PTAB/IPR and credentials. Her bio lists PTAB proceedings as a core part of her practice, and she is a named attorney on Ravgen filings giving notice of IPR petitions; she was on the teams behind the roughly ten IPR petitions / six final written decisions that upheld the Ravgen patents. I could not independently verify that she has personally argued before the PTAB or the Federal Circuit, so that should not be assumed. Bar/education: admitted in New York (2020); Harvard Law School J.D. 2019 cum laude (Journal of Law and Technology editor); Binghamton University B.A. in political science and physics, 2015 magna cum laude; Super Lawyers Rising Star (IP litigation), 2025–2026. Given her 2020 admission, her trial and appellate roles have been as part of larger Desmarais teams rather than as first chair.